ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2014-6-81-92ssmu-155Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEW AND LECTURESЕДИНЫЙ АЛГОРИТМ ДЕЙСТВИЯ ГИПОЛИПИДЕМИЧЕСКИХ ПРЕПАРАТОВ. ОСНОВЫ ПЕРВИЧНОЙ ПРОФИЛАКТИКИ АТЕРОСКЛЕРОЗА, АТЕРОМАТОЗА И КОРОНАРНОГО СИНДРОМАA SINGLE MECHANISM OF ACTION OF HYPOLIPIDEMIC DRUGS. BASIC PRINCIPLES OF PRIMARY PREVENTION OF ATHEROSCLEROSIS, ATHEROMATOSIS AND CORONARY SYNDROMEТитовВ. Н.TitovV. N.

Титов Владимир Николаевич – доктор медицинских наук, профессор, руководитель лаборатории клинической биохимии липидного обмена Института клинической кардиологии 

bolshakova_e_v@mail.ruКотловскийМ. Ю.KotlovskiyM. Yu.

Котловский Михаил Юрьевич – кандидат медицинских наук, зав. отделом газожидкостной, жидкостной и времяпролетной масс-спектрометрии ЦНИЛ

bolshakova_e_v@mail.ruКурдоякЕ. В.KurdoyakYe. V.

Курдояк Евгения Валентиновна – биолог лаборатории газожидкостной, жидкостной и времяпролетной масс-спектрометрии ЦНИЛ 

bolshakova_e_v@mail.ruЯкименкоА. В.YakimenkoA. V.

Якименко Анна Владимировна – биолог лаборатории газожидкостной, жидкостной и времяпролетной масс-спектрометрии ЦНИЛ 

bolshakova_e_v@mail.ruЯкимовичИ. Ю.YakimovichI. Yu.

Якимович Инесса Юрьевна – кандидат медицинских наук, доцент кафедры физической культуры и здоровья СибГМУ Томск 

Yakimovich Inessa Yu.

bolshakova_e_v@mail.ruАксютинаН. В.AksyutinaN. V.

Аксютина Наталья Валерьевна – кандидат медицинских наук

bolshakova_e_v@mail.ruКотловскийЮ. В.KotlovskiyYu. V.

Котловский Юрий Васильевич – доктор медицинских наук, профессор, зав. ЦНИЛ

bolshakova_e_v@mail.ruДыгайА. М.DygaiA. M.

Дыгай Александр Михайлович– заслуженный деятель науки РФ, доктор медицинских наук, профессор, академик РАН, директор 

bolshakova_e_v@mail.ruРоссийский кардиологический научно-производственный комплекс Министерства здравоохранения РФ, МоскваРоссияRussian Cardiology Research-and-Production Center, Ministry of Health, MoscowRussian FederationКрасноярский государственный медицинский университет им. проф. В.Ф. Войно-ЯсенецкогоРоссияKrasnoyarsk State Medical University named after Prof. V.F. Voino-YasenetskyRussian FederationСибирский государственный медицинский университет, ТомскРоссияSiberianStateMedicalUniversity,TomskRussian FederationНИИ фармакологии и регенеративной медицины имени Е.Д. Гольдберга, ТомскРоссияInstitute of Pharmacology and Regenerative Medicine named after E.D. Goldberg, TomskRussian Federation2014281220141368192Copyright © Титов В.Н., Котловский М.Ю., Курдояк Е.В., Якименко А.В., Якимович И.Ю., Аксютина Н.В., Котловский Ю.В., Дыгай А.М., 20142014Титов В.Н., Котловский М.Ю., Курдояк Е.В., Якименко А.В., Якимович И.Ю., Аксютина Н.В., Котловский Ю.В., Дыгай А.М.Titov V.N., Kotlovskiy M.Y., Kurdoyak Y.V., Yakimenko A.V., Yakimovich I.Y., Aksyutina N.V., Kotlovskiy Y.V., Dygai A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/155атеросклерозгиполипидемические препаратыплейотропное действиеги-перлипопротеинемияникотиновая кислотаatherosclerosishypolipidemic drugspleiotropic activityhypolipoproteinemianicotinic acidReferencesКухарук В.В. Спорные и нерешенные вопросы в проблеме атеросклероза в первой декаде XXI века // Тер. архив. 2009. № 5. С. 14–20.Kuharchuk V.V. Controversial and unresolved issues in the problem of atherosclerosis in the first decade of the XXI century. Terapevticheskiy arhiv – Therapeutic Archive, 2009, no. 5, pp. 14–20 (in Russian).Marinangeli C., Jones P. Plant sterols, marine-derived omega-3 fatty acids and other functional ingredients: a new frontier for treating hyperlipidemia // Nutr. Metab. 2010. № 7. Р. 76–82.Marinangeli C., Jones P. Plant sterols, marine-derived omega-3 fatty acids and other functional ingredients: a new frontier for treating hyperlipidemia. Nutr. Metab., 2010, no. 7, pp. 76–82.Титов В.Н. Лабораторная диагностика и диетотерапия гиперлипопротеинемий (биологические основы). М.: Медпрактика-М, 2006.Titov V.N. Laboratory diagnosis and dietetics hyper-lipoproteinemia (biological basis). Моscow, Меdpraktika-М Publ., 2006 (in Russian).Титов В.Н. Теория гуморальной патологии К. Рокитанского, целлюлярная патология Р. Вихрова и новая филогенетическая теория становления болезни. Этиология и патогенез «метаболических пандемий» // Клин. медицина. 2013. № 4. С. 4–11.Titov V.N. Theory of humoral pathology K. Rokitansky, cellular pathology and R. Vihrova new phylogenetic theory of formation of the disease. Etiology and pathogenesis of “metabolic pandemics”. Klinicheskaya medizina – Clinical Medicine, 2013, no. 4, pp. 4–11 (in Russian).Титов В.Н. Синтез насыщенных, моноеновых, ненасыщенных и полиеновых жиных кислот в филогенезе, эволюционные аспекты атеросклероза // Успехи соврем. биологии. 2012. Т. 132, № 2. С. 181–193.Titov V.N. Synthesis of saturated, monoenoic, unsaturated acids and polyene zhinyh phylogeny, evolutionary aspects of atherosclerosis. Uspehi sovremennoy biologii, 2012, vol. 132, no. 2, pp. 181–193 (in Russian).Yuan G., Al-Shali K.Z., Hegele R.A. Hypertriglyceridemia: its etiology. Effects and treatment // CMAj. 2007. V. 176, № 3. Р. 1113–1120.Yuan G., Al-Shali K.Z., Hegele R.A. Hypertriglyceridemia: its etiology. Effects and treatment. CMAj, 2007, vol. 176, no. 3, pp. 1113–1120.Barnett J., Viljoen A., Wierzbicki A.S. The need for combination drug therapies in patients with complex dyslipidemia // Curr. Cardiol. Rep. 2013. V. 15, № 8. Р. 391–399.Barnett J., Viljoen A., Wierzbicki A.S. The need for combi-nation drug therapies in patients with complex dyslipidemia. Curr. Cardiol. Rep., 2013, vol. 15, no. 8, pp. 391–399.Goldberg I.J., Eckel R.H., McPherson R. Triglycerides and heart disease, still a hypothesis // Arterioscler. Thromb. Vasc. Biol. 2011. V. 31, № 8. Р. 1716–1725.Goldberg I.J., Eckel R.H., McPherson R. Triglycerides and heart disease, still a hypothesis. Arterioscler. Thromb. Vasc. Biol., 2011, vol. 31, no. 8, pp. 1716–1725.Kurotani K., Sato M., Ejima Y. High levels of stearic acid, palmitoleic acid, and dihomo-γ-linolenic acid and low levels of linoleic acid in serum cholesterol ester are associated with high insulin resistance // Nutr. Res. 2012. V. 32, № 9. Р. 669–675.Kurotani K., Sato M., Ejima Y. High levels of stearic acid, palmitoleic acid, and dihomo-γ-linolenic acid and low levels of linoleic acid in serum cholesterol ester are associated with high insulin resistance. Nutr. Res., 2012, vol. 32, no. 9, pp. 669–675.Last A., Ference J.D., Falleroni J. Pharmacologic treatment of hyperlipidemia // Am. Fam. Physician. 2011. V. 84, № 5. Р. 551–558.Last A., Ference J.D., Falleroni J. Pharmacologic treatment of hyperlipidemia. Am. Fam. Physician., 2011, vol. 84, no. 5, pp. 551–558.Рожкова Т.А., Сусеков А.В., Соловьева Е.Ю. и др. Эффективность и переносимость статинов у больных с первичными гиперлипидемиями в амбулаторной клинической практике. // Кардиология. 2005. № 9. С. 32–34.Rogkova Т.А., Susekov А.V., Solovyova Е.Yu. et al. Efficacy and tolerability of statins in patients with primary hyperlipidemia in outpatient clinical practice. Kardiologiya, 2005, no. 9, pp. 32–34 (in Russian).Carter A.A., Gomes T., Camacho X. et al. Risk of incident diabetes among patients treated with statins: population based study // BMJ. 2013. V. 346. Р. f2610–f2617.Carter A.A., Gomes T., Camacho X. et al. Risk of incident diabetes among patients treated with statins: population based study. BMJ, 2013, vol. 346, pp. f2610–f2617.Sapmpson U.K., Linton M.F., Fazio S. Are statins diabetogenic? // Curr. Opin. Cardiol. 2011. V. 26, № 4. Р. 342–347.Sapmpson U.K., Linton M.F., Fazio S. Are statins diabeto-genic? Curr. Opin. Cardiol., 2011, vol. 26, no. 4, pp. 342–347.Tanaka S., Fukumoto Y., Nochioka K. et al. Statins exert the pleiotropic effects through small GTP-binding protein disso-ciation stimulator upregulation with a resultant Rac1 degra-dation // Arterioscler Thromb Vasc. Biol. 2013. V. 33, № 7. Р. 1591–600.Tanaka S., Fukumoto Y., Nochioka K. et al. Statins exert the pleiotropic effects through small GTP-binding protein disso-ciation stimulator upregulation with a resultant Rac1 degra-dation. Arterioscler Thromb Vasc Biol., 2013, vol. 33, no. 7, pp. 1591–600.Tenenbaum A., Fisman E.Z. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction // Cardiovasc. Diabetol. 2012. № 11. Р. 125–135.Tenenbaum A., Fisman E.Z. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc. Diabetol., 2012, no. 11, pp. 125–135.Krysiak R., Gdula-Dymek A., Okopien B. The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia // Eur. J. Clin. Pharmacol. 2011. V. 67, № 11. Р. 1109–1117.Krysiak R., Gdula-Dymek A., Okopien B. The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia. Eur. J. Clin. Pharmacol., 2011, vol. 67, no. 11, pp. 1109–1117.Demignot S., Beilstein F., Morel E. Triglyceriderich lipoproteins and cytosolic lipid droplets in enterocytes: key play-ers in intestinal physiology and metabolic disorders // Biochimie. 2013. S0300–9084(13): 00231–00239.Demignot S., Beilstein F., Morel E. Triglyceride-rich lipo-proteins and cytosolic lipid droplets in enterocytes: Key players in intestinal physiology and metabolic disorders. Biochimie, 2013, S0300–9084(13): 00231–00239.Tenenbaum A., Fisman E.Z. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? // Cardiovasc. Diabetol. 2012. № 11. Р. 140–149.Tenenbaum A., Fisman E.Z. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc. Diabetol., 2012, no. 11, pp. 140–149.Титов В.Н., Лисицын Д.М. Содержание спиртов холестерина и глицерина в плазме крови зависит от числа двой-ных связей жирных кислот в пуле липидов липопротеинов // Бюл. эксп. биологии и медицины. 2006. Т. 142, № 11. С. 521–524.Titov V.N., Lisizin D.М. The content of alcohols and glycerol cholesterol in blood plasma is dependent on the number of double bonds in the fatty acid pool lipoprotein lipids. Bulluten eksperimentalnoy biologii i medizini, 2006, vol. 142, no. 11, pp. 521–524 (in Russian).Титов В.Н. Ширяева Ю.К., Каба С.И. Субклеточные ор-ганеллы пероксисомы, реализация биологических функ-ций трофологии, гомеостаза, эндокринологии и функ-циональные связи с митохондриями (лекция). // Клин. лаб. диагностика. 2012. № 6. С. 32–42.Titov V.N., Schiryaeva Yu.К., Каba S.I. Subcellular organelles peroxisomes, the implementation of the biological functions of trophic ecology, homeostasis, endocrinology and functional connections with mitochondria (lecture). Klinicheskaya laboratornaya diagnostica, 2012, no. 6, pp. 32–42 (in Russian).Ye Y., Xing H.T., Guo Y. Hypolipidemic effect of a novel biflavonoid from shells of Camellia oleifera (Abel.) // Indian. J. Exp. Biol. 2013. V. 51, № 6. Р. 458–463.Ye Y., Xing H.T., Guo Y. Hypolipidemic effect of a novel biflavonoid from shells of Camellia oleifera (Abel.). Indian. J. Exp. Biol., 2013, vol. 51, no. 6, pp. 458–463.Yki-Jarvinen H. Thiazolidinediones // N. Engl. J. Med. 2004. V. 351. Р. 1106–1118.Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med., 2004, vol. 351, pp. 1106–1118.Midaoui A., de Champlain J. Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid // Hypertenson. 2002. V. 39. Р. 303–307.Midaoui A., de Champlain J. Prevention of hypertension, in-sulin resistance, and oxidative stress by alpha-lipoic acid. Hypertenson., 2002, vol. 39, pp. 303–307.Творогова М.Г., Лупанов В.П., Рожкова Т.А. и др. Взаимосвязь вариабельности гиполипидемического действия пробукола и особенностей нарушений обмена липопро-теидов у больных с первичной гиперлипопротеидемией // Кардиология. 1996. № 11. С. 32–37.Tvorogova М.G., Lupanov V.P., Rogkova Т.А. et al. Relationship variability hypolipidemic action of probucol and features of lipoprotein metabolism disorders in patients with primary hyperlipidaemia. Kardiologiya, 1996, no. 11, pp. 32–37 (in Russian).Творогова М.Г., Лупанов В.П., Нуралиев Э.Ю. и др. Со-ставление гиполипидемического действия пробукола в дозе 500 и 1000 мг/сутки при умеренной гиперлипопро-теидемии // Тер. архив. 1998. № 8. С. 17–21.Тvorogova М.G., Lupanov V.P., Nuraliev E.Yu. et al. Preparation of action of probucol in lipid lowering doses of 500 and 1000 mg/day in moderate hyperlipidemia. Terapevticheskiy arhiv – Therapeutic Archive, 1998, no. 8, pp. 17–21 (in Russian).Hellemans K.H., Hannaert J.C., Denys B. еt al. Susceptibi¬lity of pancreatic beta cells to fatty acids is regulated by LXR/PPARalpha-dependent stearoyl-coenzyme A desaturase // PLoS One. 2009. V. 4, № 9. Р. 7266–7278.Hellemans K.H., Hannaert J.C., Denys B. еt al. Susceptibility of pancreatic beta cells to fatty acids is regulated by LXR/PPARalpha-dependent stearoyl-coenzyme A desaturase. PLoS One, 2009, vol. 4, no. 9, pp. 7266–7278.Kromhout D., Yasuda S., Geleijnse J.M., Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? // Eur. Heart. J. 2012. № 33. Р. 436–443.Kromhout D., Yasuda S., Geleijnse J.M., Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? Eur. Heart. J., 2012, no. 33, pp. 436–443.Warensjo E., Rosell M., Hellenius M. et al. Associations between estimated fatty acid desaturase activities in serum lipids and adipose tissue in humans: links to obesity and insulin resistance // Lipids. Health. Dis. 2009. № 8. Р. 37–43.Warensjo E., Rosell M., Hellenius M. et al. Associations be-tween estimated fatty acid desaturase activities in serum lipids and adipose tissue in humans: links to obesity and insulin resistance. Lipids. Health. Dis., 2009, no. 8, pp. 37–43.Rizos E.C., Elisaf M.S. Current evidence and future perspectives of omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease // Eur. J. Pharmacol. 2013. V. 706, № 1–3. Р. 1–3.Rizos E.C., Elisaf M.S. Current evidence and future perspec-tives of omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease. Eur. J. Pharmacol., 2013, vol. 706, no. 1–3, pp. 1–3.Huang Z., Inazu A., Nohara A. et al. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of ath-erosclerosis in rabbits with severe hypercholesterolaemia // Clin. Sci. (Lond). 2002. V. 103, № 6. Р. 587–594.Huang Z., Inazu A., Nohara A. et al. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of ath-erosclerosis in rabbits with severe hypercholesterolaemia. Clin. Sci. (Lond), 2002, vol. 103, no. 6, pp. 587–594.Morton R.E., Greene D.J. The surface cholesteryl ester con-tent of donor and acceptor particles regulates CETP: a lipo-some-based approach to assess the substrate properties of lipoproteins // J. Lipid. Res. 2003. V. 44, № 7. Р. 1364–1372.Morton R.E., Greene D.J. The surface cholesteryl ester con-tent of donor and acceptor particles regulates CETP: a lipo-some-based approach to assess the substrate properties of lipoproteins. J. Lipid. Res., 2003, vol. 44, no. 7, pp. 1364–1372.Hu X., Dietz J.D., Xia C. et al. Torcetrapib induces aldo-sterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition // Endocrinology. 2009. V.150, №5. Р. 2211–2219.Hu X., Dietz J.D., Xia C. et al. Torcetrapib induces aldoste-rone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology, 2009, vol. 150, no. 5, pp. 2211–2219.Harder C., Lau P., Meng A. et al. Cholesteryl ester transfer protein (CETP) expression protects against diet induced ath-erosclerosis in SR-BI deficient mice // Arterioscler. Thromb. Vasc. Biol. 2007. V. 27, № 4. Р. 858–864.Harder C., Lau P., Meng A. et al. Cholesteryl ester transfer protein (CETP) expression protects against diet induced ath-erosclerosis in SR-BI deficient mice. Arterioscler. Thromb. Vasc. Biol., 2007, vol. 27, no. 4, pp. 858–864.Трухачева Е.П., Ежов М.В. Значение никотиновой кислоты в современной кардиологии // Рациональная фармакотерапия в Кардиологии. 2011. Т. 7, № 3. С. 365–370.Truhasheva E.P., Еgov М.V. Nicotinic acid value of modern cardiology. Razionalnaya farmakoterapiya v kardiolologii, 2011, vol. 7, no. 3, pp. 365–370 (in Russian).Wang W., Basinger A., Neese R.A. et al. Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women // Am. J. Physiol. Endocrinol. Metab. 2000. V. 279, № 1. Р. 50–59.Wang W., Basinger A., Neese R.A. et al. Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women. Am. J. Physiol. Endocrinol. Metab., 2000, vol. 279, no. 1, pp. 50–59.Thomsen C., Rasmussen O., Lousen T. et al. Differential ef-fects of saturated and monounsaturated fatty acids on post-prandial lipemia and incretin responses in healthy subjects // Am. J. Clin. Nutr. 1999. V. 69, № 6. Р. 1135–1143.Thomsen C., Rasmussen O., Lousen T. et al. Differential ef-fects of saturated and monounsaturated fatty acids on post-prandial lipemia and incretin responses in healthy subjects. Am. J. Clin. Nutr., 1999, vol. 69, no. 6, pp. 1135–1143.Ramsden C.E., Zamora D., Leelarthaepin B. et al. Use of di-etary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis // BMJ. 2013. V. 346: e8707–8714.Ramsden C.E., Zamora D., Leelarthaepin B. et al. Use of di-etary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ, 2013, vol. 346: e8707–8714.Stachowska E., Baskiewicz M., Marchlewicz M. et al. Conju-gated linoleic acids regulate triacylglycerol and cholesterol concentrations in macrophages/foam cells by the modulation of CD36 expression // Acta Biochim Pol. 2010. V. 57, № 3. Р. 379–384.Stachowska E., Baskiewicz M., Marchlewicz M. et al. Con-jugated linoleic acids regulate triacylglycerol and cholesterol concentrations in macrophages/foam cells by the modulation of CD36 expression. Acta Biochim Pol., 2010, vol. 57, no. 3, pp. 379–384.Рожкова Т.А., Титов В.Н., Амелюшкина В.А. и др. Диагностика умеренной и высокой гипертриглицеридемии у пациентов в поликлинической практике: первичные и вторичные нарушения липидного обмена // Тер. архив. 2010. № 4. С. 10–17.Rozhkova Т.А., Тitov V.N., Аmelushkina V.А. et al. Diagnosis of moderate and high hypertriglyceridemia in patients in outpatient practice: primary and secondary lipid disorders. Terapevticheskiy arhiv – Therapeutic Archive, 2010, no. 4, pp. 10–17 (in Russian).

The authors declare that there are no conflicts of interest present.